Figure 1. CDN can STING the tumor microenvironment to induce regression when combined with PD-1:PD-L1 Blockade. STINGVAX can prime tumor specific T-cells at site of vaccine injection DLN. Alternatively, STING agonist intratumorally (STINGIT) can reverse toleragenic APC in the TME to prime T-cells. With increased TIL that express IFNg, tumor PD-L1 can potentially be induced to enhance the efficacy of PD-1:PD-L1 blocking antibody.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
